Business
NovAccess Global Announces Initial Fireside Chat with Glioblastoma Patient Advocate
NovAccess Global Announces Initial Fireside Chat with Glioblastoma Patient Advocate.
About this update from Novaccess Global Inc.
[{"type":"text","content":"Topic: Benefits of Immunotherapies Versus Conventional Chemotherapy for Patients and Their Support NetworksCLEVELAND, OH / ACCESSWIRE / November 22, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the availability of its latest monthly installment in a series of fireside chat interviews, with additional sessions to be made available as company developments arise. Interviews are intended to cover important and timely topics relating to the Company, its platform technologies and the global healthcare and business environments.The fireside chat announced today is an interview conducted by NovAccess Global CEO Dr. Dwain Irvin with cancer patient advocate Cori Freeman. The interview is being streamed for public viewing over the Internet and can be accessed via the News tab of the Investors section of the NovAccess Global website at https://novaccessglobal.com/news/ and on all of the Company's social media feeds.During the interview made available today, the speakers highlight:Journeys through treatment for patients, their support systems and familiesFailures and challenges of traditional/conventional chemotherapy, where cancers often "came back with a vengeance"Choosing the appropriate treatment options for brain tumor/glioblastoma patientsBenefits of building up the immune system with immunotherapy when fighting cancerIntegrative approaches with immunotherapyNovAccess Global advancing where no measurable survivability and quality of life improvements have been achieved in 50 years for glioblastoma/brain tumorsHope found with glioblastoma immunotherapy research by Dr. Dwain IrvinSuccess stories of recovery after traditional chemotherapy using immunotherapyImproving the quality of life for patients and accelerating the path to recovery20 years of clinical trials as the foundation for NovAccess Global's lead drug candidate TLR-AD1 which recently received FDA approval for Orphan Drug DesignationNovAccess Global leveraging new technologies, additional assets, novel therapies and diagnostic data as it pursues IND for new clinical trialsNovAccess Global Fireside Chat Series Schedule:The series will include interviews on a monthly basis over the next four months. Interviews will be made available by NovAccess Global as detailed below:October...